摘要
自由基介导的损伤释放促炎性细胞因子,激活天然免疫。有人建议,早期先天性反应和缺血性组织损伤发挥作用的发展,适应性反应,这可能会导致急性肾排斥反应。肾移植前低温存储不同时间增加缺血组织损伤。在最初的损害发展小时或几天后,缺血损伤的最后阶段发生在再灌注过程中发生。修复和再生过程发生在一起,细胞凋亡,自噬和坏死,如果再生更多,则会有一个有利预期的结果是。在整个移植过程,有新的免疫和非免疫损伤的生物标志物的需求。使用这些标记物可以在潜在的肾脏捐赠者肾脏损伤的监测有很大的帮助,在急性肾损伤可以忽略,在预测急性移植物功能障碍在移植后早期阶段,或在预测慢性变化的长期随访。大量研究表明,在急性肾损伤的预测价值最高的生物标记物包括NGAL、胱抑素C、KIM-1、IL-18、和L-FABP。大多数调查表明,理想的生物标志物,以满足所有的需求在肾移植还没有确定。虽然,在许多动物模型中,新的生物标志物是新兴的预测急性和慢性移植物损伤,在人类移植分析,他们仍然不定期接受和肾活检仍然是金标准
关键词: 急性肾损伤,肾移植,急性肾功能衰竭,NGAL、胱抑素C、KIM-1、IL-18、LFABP。
Current Medicinal Chemistry
Title:Acute Renal Failure - A Serious Complication in Patients After Kidney Transplantation
Volume: 23 Issue: 19
Author(s): G. Basta-Jovanovic, Lj. Bogdanovic, M. Radunovic, M. Prostran, R. Naumovic, S. Simic-Ogrizovic, S. Radojevic-Skodric
Affiliation:
关键词: 急性肾损伤,肾移植,急性肾功能衰竭,NGAL、胱抑素C、KIM-1、IL-18、LFABP。
摘要: Free radical-mediated injury releases proinflammatory cytokines and activates innate immunity. It has been suggested that the early innate response and the ischemic tissue damage play roles in the development of adaptive responses, which may lead to acute kidney rejection. Various durations of hypothermic kidney storage before transplantation add to ischemic tissue damage. The final stage of ischemic injury occurs during reperfusion that develops hours or days after the initial insult. Repair and regeneration processes occur together with cellular apoptosis, autophagy and necrosis and a favorable outcome is expected if regeneration prevails. Along the entire transplantation time course, there is a great demand for novel immune and nonimmune injury biomarkers. The use of these markers can be of great help in the monitoring of kidney injury in potential kidney donors, where acute kidney damage can be overlooked, in predicting acute transplant dysfunction during the early post-transplant periods, or in predicting chronic changes in long term followup. Numerous investigations have demonstrated that biomarkers that have the highest predictive value in acute kidney injury include NGAL, Cystatin C, KIM-1, IL-18, and L-FABP. Most investigations show that the ideal biomarker to fulfill all the needs in renal transplant has not been identified yet. Although, in many animal models, new biomarkers are emerging for predicting acute and chronic allograft damage, in human allograft analysis they are still not routinely accepted and renal biopsy still remains the gold standard.
Export Options
About this article
Cite this article as:
G. Basta-Jovanovic, Lj. Bogdanovic, M. Radunovic, M. Prostran, R. Naumovic, S. Simic-Ogrizovic, S. Radojevic-Skodric , Acute Renal Failure - A Serious Complication in Patients After Kidney Transplantation, Current Medicinal Chemistry 2016; 23 (19) . https://dx.doi.org/10.2174/092986732319160719192019
DOI https://dx.doi.org/10.2174/092986732319160719192019 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
No-reflow: Incidence and Detection in The Cath-Lab
Current Pharmaceutical Design Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry Organ-Level Tissue Engineering Using Bioreactor Systems and Stem Cells: Implications for Transplant Surgery
Current Stem Cell Research & Therapy Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Comparison of the Acute Hematopoietic Capacities of Erythropoietin and U-74389G Concerning Hematocrit Levels
Cardiovascular & Hematological Disorders-Drug Targets Hydrogen Sulfide and its Modulation in Arterial Hypertension and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Central Nervous System Agents in Medicinal Chemistry